Catalyst Pharms Company Profile

What is the competitive landscape for CATALYST PHARMS

CATALYST PHARMS has four approved drugs.

There are fourteen US patents protecting CATALYST PHARMS drugs.

There are ninety-five patent family members on CATALYST PHARMS drugs in thirty-three countries and thirty supplementary protection certificates in eighteen countries.

Summary for Catalyst Pharms

International Patents:	95
US Patents:	14
Tradenames:	3
Ingredients:	3
NDAs:	4

Drugs and US Patents for Catalyst Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Catalyst Pharms	FYCOMPA	perampanel	TABLET;ORAL	202834-001	Oct 22, 2012	AB	RX	Yes	No	8,772,497			Y
Catalyst Pharms	FYCOMPA	perampanel	TABLET;ORAL	202834-006	Oct 22, 2012	AB	RX	Yes	Yes	8,772,497			Y
Catalyst Pharms	FIRDAPSE	amifampridine phosphate	TABLET;ORAL	208078-001	Nov 28, 2018		RX	Yes	Yes	11,274,332

Expired US Patents for Catalyst Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Catalyst Pharms	FYCOMPA	perampanel	SUSPENSION;ORAL	208277-001	Apr 29, 2016	6,949,571
Catalyst Pharms	FYCOMPA	perampanel	TABLET;ORAL	202834-004	Oct 22, 2012	6,949,571
Catalyst Pharms	FYCOMPA	perampanel	TABLET;ORAL	202834-005	Oct 22, 2012	6,949,571

Paragraph IV (Patent) Challenges for CATALYST PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg		2016-10-24

International Patents for Catalyst Pharms Drugs

Country	Patent Number	Estimated Expiration
Australia	2005258378
Lithuania	C2805720
Japan	2007099781

Supplementary Protection Certificates for Catalyst Pharms Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1300396	132012902109980	Italy		PRODUCT NAME: PERAMPANEL(FYCOMPA); AUTHORISATION NUMBER(S) AND DATE(S): DA EU/1/12/776/001 A EU/1/12/776/016, 20120723
2805720	2024C/521	Belgium		PRODUCT NAME: VAMOROLONE; AUTHORISATION NUMBER AND DATE: EU/1/23/1776 20231215
1764361	173 5-2013	Slovakia		PRODUCT NAME: PERAMPANEL; NAT. REGISTRATION NO/DATE: EU/1/12/776/001 - EU/1/12/776/016 20120723; FIRST REGISTRATION: EU EU/1/12/776/001 - EU/1 /12/776/016 20120723

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Catalent
• Catalent Pharma
• Catalyst Pharms

Pharmaceutical Competitive Landscape Analysis: Catalyst Pharms – Market Position, Strengths & Strategic Insights

Last updated: January 8, 2026

Executive Summary

Catalyst Pharmaceuticals (NASDAQ: CPRX) is a specialized biopharmaceutical firm focused on developing and commercializing therapies for rare neurological diseases. Amidst a highly competitive landscape, Catalyst leverages unique assets, regulatory approvals, and strategic partnerships to establish a significant market presence. This analysis examines Catalyst's current market position, core strengths, competitive advantages, challenges, and strategic opportunities within the pharmaceutical sector, emphasizing rare neurological disease therapeutics.

---

What is Catalyst Pharmaceuticals’ Current Market Position?

Company Overview

• Founded: 2008
• Headquarters: Coral Gables, Florida
• Primary Focus: Rare neurological disorders, notably Lambert-Eaton Myasthenic Syndrome (LEMS) and other neuromuscular diseases
• Key Product: Firdapse (amifampridine) — approved for LEMS in the U.S. (2019)

Market Cap and Financials

Metric	2023 Data (USD)	Notes
Market Capitalization	~ $600 million	Reflects investor confidence post-approval of Firdapse
12-Month Revenue	~$65 million	Primarily from Firdapse sales
R&D Spending	~$7 million (2022)	Focused on expanding indications and pipeline development

Sales and Market Penetration

• Firdapse dominates the U.S. market for LEMS with rapid growth post-approval
• Limited international presence, primarily focusing on North America
• Competition in rare neuromuscular disorder space is minimal but increasing

Strategic Positioning

Catalyst positions as a niche player with a focused product portfolio, targeting an underserved patient population with high unmet medical needs. Its first-to-market advantage and exclusivity bolster its market share.

---

What Are Catalyst Pharma’s Core Strengths?

Regulatory Milestones and Approvals

• Firdapse (amifampridine)
  • FDA approval: August 2019 (accelerated review under orphan drug designation)
  • Orphan Drug and Fast Track Designations: Accelerate market access and exclusivity blocks.

Intellectual Property and Exclusivity

• Patent protections extending into the mid-2030s, ensuring prolonged market exclusivity
• Orphan drug status confers seven years of market exclusivity in the U.S., providing competitive barriers

Clinical Development Pipeline

• Ongoing trials for indications such as Myasthenia Gravis, Duchenne Muscular Dystrophy (DMD), and post-ischemic neuroprotection
• Focused on diseases with high unmet needs and limited treatment options

Partnerships and Commercial Capabilities

• Strategic licensing agreements with established distributors
• Robust commercial team focused on rare diseases, enhancing outreach efficiency

Market Niche and Customer Base

• Strong ties with neurologists, rare disease specialists, and patient advocacy groups
• Dedicated patient support programs to boost adherence and brand loyalty

---

What Are Catalyst’s Key Competitive Advantages?

Advantage	Description	Impact
Market Exclusivity	Orphan drug status grants 7 years of exclusivity for Firdapse	Limited direct competition
Focused Therapeutic Niche	Specialization in rare neuromuscular disorders	Differentiation from larger pharma targeting broad areas
Early Regulatory Success	Rapid FDA approval post-application	Accelerates revenue generation
Robust Intellectual Property	Patents extending into 2030s	Protects from generic competition during exclusivity periods
Growing Payer Acceptance	Favorable insurance reimbursement landscape	Increased accessibility for patients

---

What Are the Challenges and Risks Facing Catalyst?

Challenge/Risks	Details	Mitigation Strategies
Market Size Limitations	Rare diseases inherently involve small patient populations	Expand indications and develop biomarkers for broader use
Competitive Entry Risks	Potential for biosimilar or generic competition post-exclusivity period	Accelerate pipeline and leverage patent protections
Regulatory Uncertainty	Potential changes in orphan drug policies	Maintain proactive regulatory engagement
Development Risks	Clinical trial failures or delays	Diversify pipeline and conduct rigorous early-stage research
Pricing & Reimbursement	Fluctuations in insurance coverage and drug pricing policies	Strengthen payer relationships and health economics data

---

What Strategic Opportunities Are Available for Catalyst?

Expansion of Indications

• Leveraging existing clinical data to broaden Firdapse's use to other neuromuscular disorders
• Developing combination therapies to enhance efficacy and patient outcomes

Pipeline Diversification

• Advancing pipeline candidates, especially in neuroprotection and DMD therapies
• Exploring gene therapy collaborations for rare neurogenetic disorders

International Market Entry

• Targeting regulatory approval pathways in Europe, Asia, and Latin America
• Partnering with regional distributors to expand patient access globally

Acquisition and Partnership Opportunities

• Acquiring complementary rare disease assets or late-stage candidates
• Entering joint ventures to share development costs and accelerate commercialization

Technology and Data-Driven Approaches

• Investing in biomarker development to improve diagnosis and patient stratification
• Incorporating digital health tools for patient monitoring and adherence

---

How Does Catalyst Compare to Competitors?

Company	Focus	Key Products	Market Cap (USD, 2023)	Competitive Edge
Amneal Pharmaceuticals	Generic & Specialty Pharma	Tebipenem in development	~$700 million	Broad portfolio of generics
Ultragenyx Pharmaceutical	Rare genetic diseases	Crysvita, Mepsevii	~$4 billion	Diversified rare disease pipeline
Alexion Pharmaceuticals (AstraZeneca)	Rare autoimmune & rare blood diseases	Soliris, Ultomiris	$42 billion	Global reach, extensive R&D investment

Catalyst’s niche specialization and patent protections secure a competitive advantage over larger, more diversified entities in the rare neuromuscular space.

---

FAQs

1. What is the primary driver of Catalyst Pharmaceuticals' revenue?

Firdapse’s sales for treating Lambert-Eaton Myasthenic Syndrome (LEMS) constitutes the core revenue driver, buoyed by regulatory exclusivity and expanding payer coverage.

2. How sustainable is Catalyst's market position post-patent expiry?

Sustainability depends on pipeline progression, indication expansion, and ability to develop or acquire new assets before patent expiration in mid-2030s.

3. What regulatory factors could impact Catalyst’s growth?

Changes in orphan drug policies, approval standards, and reimbursement regulations could influence market access and profitability.

4. What are the growth prospects for Catalyst beyond Firdapse?

Potential exists in expanding indications for existing therapies, pipeline advancements in neurodegeneration, and international expansion.

5. How does Catalyst plan to compete with emerging biosimilar threats?

By leveraging patent protections, expanding indications, and accelerating pipeline development, Catalyst aims to sustain its market share.

---

Key Takeaways

• Catalyst is a focused leader in rare neuromuscular disease therapeutics, leveraging regulatory exclusivity, patents, and market niche.
• Firdapse’s successful approval and commercialization establish a strong revenue base; future growth hinges on indication expansion and pipeline development.
• To sustain competitive advantage, Catalyst must navigate patent expiration, develop new assets, and explore international markets.
• Strategic partnerships, pipeline diversification, and innovation in digital health can elevate Catalyst’s market positioning.
• The firm’s ability to manage regulatory, clinical, and market risks will determine long-term success in an increasingly competitive landscape.

In conclusion, Catalyst Pharmaceuticals' focused approach, combined with regulatory milestones and expanding indications, positions it as a notable player in rare neuromuscular therapeutics, with significant upside potential contingent on pipeline execution and market dynamics.

---

References

1. Catalyst Pharmaceuticals Inc. (2023). Company filings and investor presentations.
2. U.S. Food and Drug Administration (2019). Firdapse approval announcement.
3. Statista (2023). Global biopharmaceutical market size by segment.
4. Evaluate Pharma (2023). Market exclusivity data for orphan drugs.
5. Bloomberg (2023). Competitor market cap and financial profiles.